orlistat has been researched along with Precancerous-Conditions* in 1 studies
1 other study(ies) available for orlistat and Precancerous-Conditions
| Article | Year |
|---|---|
The anti-obesity agent Orlistat is associated to increase in colonic preneoplastic markers in rats treated with a chemical carcinogen.
Orlistat is an anti-obesity agent that increases the fecal fat excretion, which promotes colon carcinogenesis. Therefore, the present study was designed to verify the effects of Orlistat on the formation of rat colonic aberrant crypt foci (ACF) and cell proliferation evaluated by the PCNA method. Male Wistar rats received either a standard diet or a high fat diet (HFD), supplemented or not with Orlistat (200mg/kg chow) and two doses of the carcinogen dimethyl-hydrazine (25mg/Kg). After 30 days, Orlistat was associated to a significant increase in the number of colonic ACFs and cell proliferation in DMH-treated animals, independently of the HFD. Topics: 1,2-Dimethylhydrazine; Animals; Anti-Obesity Agents; Carcinogens; Cell Proliferation; Colonic Neoplasms; Intestinal Mucosa; Lactones; Lipase; Male; Orlistat; Precancerous Conditions; Proliferating Cell Nuclear Antigen; Rats; Rats, Wistar | 2006 |